Skip to main content
The Egyptian Journal of Bronchology
Download PDF

Correlation between serum periostin biomarker, spirometric airflow limitation, and airway dimensions by multidetector computed tomography in bronchial asthma

Egyptian Journal of Bronchology volume 12, pages 160–172 (2018)Cite this article

Abstract

Background

Periostin has shown to be involved in the many aspects of allergic inflammation, such as acceleration of allergen-induced eosinophil recruitment, development of a Th2 phenotype, increased expression of inflammatory mediators, and airway remodeling and fibrosis in bronchial asthma and that fibrosis is one factor that causes steroid resistance or hyporesponsiveness in bronchial asthma.

Aim

This study aimed to evaluate the possible role of serum periostin as a biomarker for airway inflammation, for predicting the patient’s possible response to inhaled corticosteroids (ICS) after its regular use and its correlation with disease severity and control compared with functional and radiological findings.

Patients and methods

Sixty nonsmoker, asthmatic patients of at least 20 years of age and 20 control healthy nonsmokers with matched age and sex were included. Patients were then subclassified into two: first, according to the asthma severity into mild, moderate, and severe and then according to asthma control (controlled, poorly controlled, and uncontrolled). Serum periostin, spirometry, and multidetector computed tomography were performed for all included populations.

Results

There was significant statistical direct relation with increased serum periostin level and wall area and bronchial wall thickening (BWT) with asthma severity and all showed high significant increase among patients with uncontrolled than those with controlled asthma. Highly significant statistical direct correlation was found between BWT and serum periostin level. There was highly statistically significant decreased serum periostin level and BWT among the steroid-treated group of patients than in steroid-naive asthma (nonsteroid treated group of patients) which were significantly decreased after regular daily use of ICS for 6 months and also among uncontrolled patients after being adequately controlled than their baseline states.

Conclusion

Serum periostin marker and BWT had a significant, sensitive, accurate clinically relevant indicative value (especially when combined) as regards asthma control and severity and probable adequate response to ICS. Serum periostin not only could be a reliable biomarker for eosinophilic inflammation but also may contribute to the development of airway remodeling as assessed by multidetector computed tomography.

References

  1. Venzel S. Asthma phynotypes:the evolution from clinical to molecular approaches. Nat Med 2012;18:716–725.

    Google Scholar 

  2. Rajanandh M, Nageswari A, Ilango K. Pulmonary function assessment in mild to moderate persistent asthma patients receiving montelukast, doxofylline and tiotropium with budesonide:a randomized controlled study. Clin Ther 2014;36:526–533.

    CAS  PubMed  Google Scholar 

  3. Güder G, Brenner S, Angermann CE. GOLD or lower limit of normal definition? A comparison with expert-based diagnosis of chronic obstructive pulmonary disease in a prospective cohort-study. Respir Res 2012;13:13–20.

    PubMed  PubMed Central  Google Scholar 

  4. Walford M, Doherty T. Diagnosis and management of eosinophilic asthma:a US perspective. J Asthma Allergy 2014;7:53–65.

    PubMed  PubMed Central  Google Scholar 

  5. Makoto H, Junichi O, Kenta A. Association of airway wall thickness with serum periostin in steroid-naive asthma. Allergy Asthma Proc 2016;44:37–45.

    Google Scholar 

  6. Kanemitsu Y, Beasley R, Hurd S, Kudo E. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009;360:985–993.

    Google Scholar 

  7. Matsumoto H. Serum periostin:a novel biomarker for asthma management. Allergol Int 2014;63:153–160.

    CAS  PubMed  Google Scholar 

  8. Masoli N, Fabian D, Holt S. Global Initiative for Asthma (GINA) Program. The global burden of asthma:executive summary of the GINA Dissemination Committee report. Allergy 2004;59:469–478.

    PubMed  Google Scholar 

  9. Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma:executive summary of the GINA, pocket guide for health professionals; updated 2015, Dissemination Committee report. Allergy 2016;59:469–478.

    Google Scholar 

  10. Rabe K, Adachi M, Lai C. Worldwide severity and control of asthma in children and adults:the global asthma insights and reality surveys. J Allergy Clin Immunol 2014;114:40–47.

    Google Scholar 

  11. Walker C, Gupta S, Müller N, Hartley B, Kudo E. Computed tomography scans in severe asthma:utility and clinical implications. Curr Opin Pulm Med 2012;18:42–47.

    PubMed  PubMed Central  Google Scholar 

  12. Dame R, Magnussen J, Beren N. Greater parallel heterogeneity of airway narrowing and airway closure in asthma measured by high-resolution CT. Thorax 2015;17:1163–1170.

    Google Scholar 

  13. Woodruff P, Modrek B, Choy D. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 2009;180:388–395.

    CAS  PubMed  PubMed Central  Google Scholar 

  14. Kanemitsu Y, Matsumoto H, Izuhara K. Increased periostin associates with greater airflow limitation in patients receiving inhaled corticosteroids. J Allergy Clin Immunol 2013;132:305–312.

    CAS  PubMed  Google Scholar 

  15. Rajanandh M, Nageswari A, Ilango K, Kudo E, Choy D, Erickson R. Effect of two controller medications with inhaled corticosteroid in mild to moderate persistent asthma patients. J Med Sci 2014;14:181–186.

    Google Scholar 

  16. Jia G, Erickson R, Choy G. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol 2012;130:647–654.

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Vollme W. Assessment of asthma control and severity. Ann Allergy Asthma Immunol 2014;93:409–413.

    Google Scholar 

  18. Hitasha R, Laurie L, Junya O. Serum periostin in asthma:a potential biomarker for stratification in severe treatment-resistant asthma. Eur Respir J 2011;37:1119–1127.

    Google Scholar 

  19. Katarzyna G, Marta M, King T, Patrycja N. Comparative study of periostin expression in different respiratory samples in patients with asthma and chronic obstructive pulmonary disease. Pol Arch Med Wewn 2016;124:124–136.

    Google Scholar 

  20. Conway S, Izuhara S, Kudo E, Müller N. The role of periostin in tissue remodeling across health and disease. Cell Mol Life Sci 2014;71:1279–1288.

    CAS  PubMed  Google Scholar 

  21. Nakamura Y, Nagashima H, Ohta S. Periostin in the bronchial lavage fluid of asthma patients. Allergol Int 2015;64:209–216.

    CAS  PubMed  Google Scholar 

  22. Sidhu S, Yuan R, Innes A. Roles of epithelial cell-derived periostin in TGF-beta activation, collagen production, and collagen gel elasticity in asthma. Proc Nati Acad Sci USA 2010;107:169–175.

    Google Scholar 

  23. Wagener Q, Nijs S, Lutter R. External validation of blood eosinophils, FE (NO) and serum periostin as surrogates for sputum eosinophils in asthma. Thorax 2015;70:115–120.

    CAS  PubMed  Google Scholar 

  24. Makoto H, Shin M, Hiroshi H. Correlation between airflow limitation and airway dimensions assessed by multidetector CT in asthma. Respir Med 2013;104:794–800.

    Google Scholar 

  25. Stephen P, Petersa G, Fergusonb M. Uncontrolled asthma:a review of the prevalence, disease burden and options for treatment. Respir Med 2006;100:1139–1151.

    Google Scholar 

  26. Dolan C, Fraher K, Bleecker E. Design and baseline characteristics of the epidemiology and natural history of asthma:outcomes and treatment regimens (TENOR) study:a large cohort of patients with severe or difficult to treat asthma. Ann Allergy Asthma Immunol 2014;92:32–39.

    Google Scholar 

  27. Masako M, Hiroki K, Koichi F. Phenotype of asthma related with high serum periostin levels. Allergol Int 2015;64:175–180.

    Google Scholar 

  28. Habernau M, Del Pozo A, Rodríguez V. Role of periostin in uncontrolled asthma. J Investig Allergol Clin Immunol 2017;27:291–301

    CAS  Google Scholar 

  29. Carr D, Hibon S, Rubens M. Peripheral airways obstruction on high-resolution computed tomography in chronic severe asthma. Respir Med 2014;92:448–453.

    Google Scholar 

  30. HarmanciG, Kebapci S, Metintas M. High-resolution computed tomography findings are correlated with disease severity in asthma. Respiration 2012;6:427–433.

    Google Scholar 

  31. Paganin F, Seneterre E, Chanez P, Kudo E. Computed tomography of the lungs in asthma:influence of disease severity and etiology. Am J Respir Crit Care Med 2011;153:125–131.

    Google Scholar 

  32. Park C, Müller N, Worthy S. Airway obstruction in asthmatic and healthy individuals:inspiratory and expiratory thin-section CT findings. Radiology 2013;204:369–375.

    Google Scholar 

  33. Lynch D, Newell J, Tschomper B, Erickson R. Uncomplicated asthma in adults:comparison of CT appearance of the lungs in asthmatic and healthy subjects. Radiology 2014;188:829–833.

    Google Scholar 

  34. Rajanandh M, Hartley R, Solberg O. Assessment of various second-line medications in addition to inhaled corticosteroid in asthma patients:a randomized controlled trial. Clin Exp Pharmacol Physiol 2014;205:7–13.

    Google Scholar 

  35. James F, Irene B, Justin T, Kudo S. Serum periostin in obstructive airways disease. Eur Respir J 2016;47:1383–1391.

    Google Scholar 

  36. Woodruff P, Boushey H, Dolganov G. Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. N Engl J Med 2007;104:158–163.

    Google Scholar 

  37. Boushey H, Sorkness C, King T. Daily versus as-needed corticosteroids for mild persistent asthma. N Engl J Med 2010;352:1519–1528.

    Google Scholar 

  38. Kanemitsu D, Matsumoto H, King T, Izuhara K. Increased periostin associates with greater airflow limitation in patients receiving inhaled corticosteroids. J Allergy Clin Immunol 2013;132:305–312.

    CAS  PubMed  Google Scholar 

  39. Taylor D. Using biomarkers in the assessment of airways disease. J Allergy Clin Immunol 2011;128:927–934.

    CAS  PubMed  Google Scholar 

  40. Szefler S, Wenzel S, Müller N, Brown R. Asthma outcomes:biomarkers. J Allergy Clin Immunol 2012;129:19–23.

    Google Scholar 

  41. Jodie L, Simpson S, Ian A. Periostin levels and eosinophilic inflammation in poorly-controlled asthma. BMC Pulm Med 2016;1:67–72.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Chest Diseases, Ain Shams University, 4, Abo-Elhol St, El-Korba, Heliopolis, Cairo, Egypt

    Eman R. Al-Adawy MD, PhD & Ashraf A. Gomaa

  2. Department of Radiology, Ain Shams University, Cairo, Egypt

    Ahmed M. Mohamed

Authors
  1. Eman R. Al-Adawy MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ashraf A. Gomaa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ahmed M. Mohamed
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eman R. Al-Adawy MD, PhD.

Additional information

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Al-Adawy, E.R., Gomaa, A.A. & Mohamed, A.M. Correlation between serum periostin biomarker, spirometric airflow limitation, and airway dimensions by multidetector computed tomography in bronchial asthma. Egypt J Bronchol 12, 160–172 (2018). https://doi.org/10.4103/ejb.ejb_3_18

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.4103/ejb.ejb_3_18

Keywords